1958. Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants With Bronchiolitis, in the Phase 1b Study 53718678RSV1005

BACKGROUND: JNJ-8678 is a RSV-specific fusion inhibitor and a potential new treatment for respiratory infections caused by RSV. Data from a Phase 1b study of PK, safety and antiviral effects in hospitalized RSV-infected infants are presented. METHODS: 37 and 7 patients, respectively, were randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinon-Torres, Federico, Rusch, Sarah, Huntjens, Dymphy, Remmerie, Bart, Vingerhoets, Johan, McFadyen, Katie, Ferrero, Fernando, Baraldi, Eugenio, Conejo, Pablo Rojo, Epalza, Cristina, Stevens, Marita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252897/
http://dx.doi.org/10.1093/ofid/ofy210.1614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252897/
http://dx.doi.org/10.1093/ofid/ofy210.1614

Ejemplares similares